Memed is utilizing machine learning and AI to enhance the immune system's diagnostic capabilities for infectious diseases and inflammatory disorders. The Memed BV test differentiates between bacterial and viral infections, aiding physicians in antibiotic treatment decisions to combat antimicrobial resistance. The Memed Key platform provides rapid immunoassay results, significantly improving clinical decision-making and has been validated through extensive clinical studies.

1. MeMed

2. Translating the complex signaling of the immune
system into simple diagnostic insights.

3. We are applying machine learning and artificial intelligence to the
complex signaling of the world's most accurate diagnostic system,
the immune system.

4. Our AI-based diagnostics address key clinical and
medical challenges in infectious diseases and
inflammatory disorders.

5. MeMed BV is a pioneering test for distinguishing
between bacterial and viral infections that relies on
the most accurate detection system - the body's
immune system.

6. MeMed BV aims to support physicians in making
better informed antibiotic treatment decisions and
tackling antimicrobial resistance - one of the
biggest healthcare challenges of our time.

7. MeMed Key is a first of its kind immunoassay
platform, that opens the way to measuring
multiple proteins with central lab performance
at the point-of-need.

8. Key will deliver MeMed BV test results in 15
minutes.

9. Our technology and products have been developed
and rigorously validated in large multinational clinical
studies encompassing thousands of patients and
published in high impact scientific and medical
journals.

10. MeMed Co-Founder & CEO, Dr. Eran Eden presented
at ECCMID 2021, with highlights from the Observer
study “A host assay comprising TRAIL, IP-10 and
CRP can improve antibiotic treatment decisions for
viral PCR positive adults by accurately ruling out co-
infection”